Chemotherapy with low-dose bevacizumab and carboplatin in the treatment of a patient with recurrent cervical cancer

S. J. Tan, Y. H. Juan, P. T. Fu, M. H. Yu, H. C. Lai

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Management of patients with recurrent or advanced cervical cancer is a challenge. Concurrent chemotherapy has become the mainstay of treatment and platinum remains the most effective single agent. Combinations of other agents have not demonstrated significant advantages. The application of angiogenesis inhibitors such as bevacizumab, an antibody inhibiting vascular endothelial growth factor, in metastatic or advanced cervical cancer remains to be evaluated. We present the case of a patient with platinum-resistant recurrent cervical cancer treated with low-dose bevacizumab and carboplatin, with resultant improved disease progression and tolerable toxicity profiles.

Original languageEnglish
Pages (from-to)350-353
Number of pages4
JournalEuropean Journal of Gynaecological Oncology
Volume31
Issue number3
Publication statusPublished - 2010
Externally publishedYes

Fingerprint

Carboplatin
Uterine Cervical Neoplasms
Platinum
Drug Therapy
Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A
Disease Progression
Therapeutics
Antibodies
Bevacizumab

Keywords

  • Bevacizumab
  • Cervical cancer
  • Metronomic

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Chemotherapy with low-dose bevacizumab and carboplatin in the treatment of a patient with recurrent cervical cancer. / Tan, S. J.; Juan, Y. H.; Fu, P. T.; Yu, M. H.; Lai, H. C.

In: European Journal of Gynaecological Oncology, Vol. 31, No. 3, 2010, p. 350-353.

Research output: Contribution to journalArticle

@article{3b4776d3be644a74a079e6ff7fab6964,
title = "Chemotherapy with low-dose bevacizumab and carboplatin in the treatment of a patient with recurrent cervical cancer",
abstract = "Management of patients with recurrent or advanced cervical cancer is a challenge. Concurrent chemotherapy has become the mainstay of treatment and platinum remains the most effective single agent. Combinations of other agents have not demonstrated significant advantages. The application of angiogenesis inhibitors such as bevacizumab, an antibody inhibiting vascular endothelial growth factor, in metastatic or advanced cervical cancer remains to be evaluated. We present the case of a patient with platinum-resistant recurrent cervical cancer treated with low-dose bevacizumab and carboplatin, with resultant improved disease progression and tolerable toxicity profiles.",
keywords = "Bevacizumab, Cervical cancer, Metronomic",
author = "Tan, {S. J.} and Juan, {Y. H.} and Fu, {P. T.} and Yu, {M. H.} and Lai, {H. C.}",
year = "2010",
language = "English",
volume = "31",
pages = "350--353",
journal = "European Journal of Gynaecological Oncology",
issn = "0392-2936",
publisher = "S.O.G. CANADA Inc.",
number = "3",

}

TY - JOUR

T1 - Chemotherapy with low-dose bevacizumab and carboplatin in the treatment of a patient with recurrent cervical cancer

AU - Tan, S. J.

AU - Juan, Y. H.

AU - Fu, P. T.

AU - Yu, M. H.

AU - Lai, H. C.

PY - 2010

Y1 - 2010

N2 - Management of patients with recurrent or advanced cervical cancer is a challenge. Concurrent chemotherapy has become the mainstay of treatment and platinum remains the most effective single agent. Combinations of other agents have not demonstrated significant advantages. The application of angiogenesis inhibitors such as bevacizumab, an antibody inhibiting vascular endothelial growth factor, in metastatic or advanced cervical cancer remains to be evaluated. We present the case of a patient with platinum-resistant recurrent cervical cancer treated with low-dose bevacizumab and carboplatin, with resultant improved disease progression and tolerable toxicity profiles.

AB - Management of patients with recurrent or advanced cervical cancer is a challenge. Concurrent chemotherapy has become the mainstay of treatment and platinum remains the most effective single agent. Combinations of other agents have not demonstrated significant advantages. The application of angiogenesis inhibitors such as bevacizumab, an antibody inhibiting vascular endothelial growth factor, in metastatic or advanced cervical cancer remains to be evaluated. We present the case of a patient with platinum-resistant recurrent cervical cancer treated with low-dose bevacizumab and carboplatin, with resultant improved disease progression and tolerable toxicity profiles.

KW - Bevacizumab

KW - Cervical cancer

KW - Metronomic

UR - http://www.scopus.com/inward/record.url?scp=77954124424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954124424&partnerID=8YFLogxK

M3 - Article

C2 - 21077488

AN - SCOPUS:77954124424

VL - 31

SP - 350

EP - 353

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 3

ER -